Compare LBRX & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | STAA |
|---|---|---|
| Founded | 2015 | 1982 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 867.9M |
| IPO Year | N/A | 1995 |
| Metric | LBRX | STAA |
|---|---|---|
| Price | $27.89 | $32.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $46.60 | $22.81 |
| AVG Volume (30 Days) | 140.2K | ★ 861.8K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | N/A | ★ $239,442,000.00 |
| Revenue This Year | N/A | $30.82 |
| Revenue Next Year | N/A | $8.41 |
| P/E Ratio | ★ N/A | $321.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.40 | $15.59 |
| 52 Week High | $33.47 | $35.87 |
| Indicator | LBRX | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 79.35 |
| Support Level | $22.39 | $23.75 |
| Resistance Level | $33.47 | N/A |
| Average True Range (ATR) | 1.68 | 1.51 |
| MACD | -0.60 | 0.37 |
| Stochastic Oscillator | 11.96 | 66.34 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.